Laruelle M
Department of Psychiatry and Radiology, Columbia University College of Physicians and Surgeons and New York State Psychiatric Institute, New York 10032, USA.
J Cereb Blood Flow Metab. 2000 Mar;20(3):423-51. doi: 10.1097/00004647-200003000-00001.
Several groups have provided evidence that positron emission tomography (PET) and single-photon emission computed tomography (SPECT) neuroreceptor imaging techniques might be applied to measure acute fluctuations in dopamine (DA) synaptic concentration in the living human brain. Competition between DA and radioligands for binding to D2 receptor is the principle underlying this approach. This new application of neuroreceptor imaging provides a dynamic measurement of neurotransmission that is likely to be informative to our understanding of neuropsychiatric conditions. This article reviews and discusses the body of data supporting the feasibility and potential of this imaging paradigm. Endogenous competition studies performed in rodents, nonhuman primates, and humans are first summarized. After this overview, the validity of the model underlying the interpretation of these imaging data is critically assessed. The current reference model is defined as the occupancy model, since changes in radiotracer binding potential (BP) are assumed to be directly caused by changes in occupancy of D2 receptors by DA. Experimental data supporting this model are presented. The evidence that manipulation of DA synaptic levels induces change in the BP of several D2 radiotracers (catecholamines and benzamides) is unequivocal. The fact that these changes in BP are mediated by changes in DA synaptic concentration is well documented. The relationship between the magnitude of BP changes measured with PET or SPECT and the magnitude of changes in DA concentration measured by microdialysis supports the use of these noninvasive techniques to measure changes in neurotransmission. On the other hand, several observations remain unexplained. First, the amphetamine-induced changes in the BP of D2 receptor antagonists [123I]IBZM and [11C]raclopride last longer than amphetamine-induced changes in DA extracellular concentration. Second, nonbenzamide D2 receptor antagonists, such as spiperone and pimozide, are not affected by changes in DA release, or are affected in a direction opposite to that predicted by the occupancy model. Similar observations are reported with D1 radiotracers. These results suggest that the changes in BP following changes in DA concentration might not be fully accounted by a simple occupancy model. Specifically, the data are reviewed supporting that agonist-mediated receptor internalization might play an important role in characterizing receptor-ligand interactions. Finally, it is proposed that a better understanding of the mechanism underlying the effects observed with benzamides is essential to develop this imaging technique to other receptor systems.
多个研究小组已提供证据表明,正电子发射断层扫描(PET)和单光子发射计算机断层扫描(SPECT)神经受体成像技术可用于测量活体人脑中多巴胺(DA)突触浓度的急性波动。DA与放射性配体竞争结合D2受体是该方法的基本原理。神经受体成像的这一新应用提供了神经传递的动态测量,这可能有助于我们理解神经精神疾病。本文回顾并讨论了支持这种成像模式的可行性和潜力的数据。首先总结了在啮齿动物、非人灵长类动物和人类中进行的内源性竞争研究。在此概述之后,对解释这些成像数据的基础模型的有效性进行了批判性评估。当前的参考模型被定义为占据模型,因为放射性示踪剂结合潜能(BP)的变化被认为是由DA对D2受体占据率的变化直接引起的。给出了支持该模型的实验数据。DA突触水平的操纵会导致几种D2放射性示踪剂(儿茶酚胺和苯甲酰胺)的BP发生变化,这一证据是明确的。BP的这些变化是由DA突触浓度的变化介导的,这一点有充分的文献记载。用PET或SPECT测量的BP变化幅度与用微透析测量的DA浓度变化幅度之间的关系支持使用这些非侵入性技术来测量神经传递的变化。另一方面,一些观察结果仍无法解释。首先,苯丙胺引起的D2受体拮抗剂[123I]IBZM和[11C]雷氯必利的BP变化持续时间比苯丙胺引起的DA细胞外浓度变化持续时间更长。其次,非苯甲酰胺类D2受体拮抗剂,如螺哌隆和匹莫齐特,不受DA释放变化的影响,或者受到与占据模型预测相反方向的影响。用D1放射性示踪剂也报道了类似的观察结果。这些结果表明,DA浓度变化后BP的变化可能不能完全用简单的占据模型来解释。具体而言,回顾了支持激动剂介导的受体内化可能在表征受体-配体相互作用中起重要作用的数据。最后,有人提出,更好地理解苯甲酰胺类药物所观察到的效应的潜在机制对于将这种成像技术应用于其他受体系统至关重要。